Streetbeat News

Products Services

BIDU

BIRK

COST

GOOG

GSK

HUM

LVMHF

MGM

MNKTQ

NVO

QABSY

TPST

WBA

Several companies are in the news for various reasons. Alphabet and Discord are facing ethical concerns over Google's AI chatbot, Bard. MGM Resorts snubbed hackers' ransom demands after a cyberattack. Costco is accused of sharing confidential health data with Meta Platforms. Humana has appointed a new CEO. Novo Nordisk has stopped a kidney trial due to early signs of efficacy. Walgreens has appointed a new CEO. GSK has settled a lawsuit. LVMH reported a 9% organic revenue growth in Q3. Qantas Airways is overhauling its board. Tempest Therapeutics' stock soared after positive results from a clinical trial. Tech giants Baidu, Huawei, and Alibaba are setting standards for autonomous driving in China. Blackstone is in talks to acquire a stake in Disney's Indian subsidiary. Mallinckrodt's bankruptcy plan was approved. Birkenstock has priced its IPO.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 1:36 pm

ABT

Abbott Laboratories (ABT) is planning to enter the consumer wearables market as COVID-19 testing sales decline. The company's CEO, Robert Ford, announced the strategic move at the HLTH conference in Las Vegas. Abbott's latest wearable sensor, Lingo, which tracks glucose levels and offers personalized coaching recommendations, is set to be released in the U.S. next year. The company is preparing to submit its Lingo filing to the FDA by the end of the year.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 1:29 pm

STLA

Stellantis N.V. (NYSE: STLA) and Samsung SDI have announced Kokomo, Indiana, as the second site for their electric vehicle battery manufacturing facility in the U.S. The companies will invest over $3.2 billion in the new facility, which will be co-located with a gigafactory currently under construction. The second facility is expected to start production in early 2027, with an annual capacity of 34 gigawatt hours. The total investment for both facilities is expected to be more than $6.3 billion, creating about 2,800 new jobs.

Portfolio Pulse from Lekha Gupta

October 11, 2023 | 1:28 pm

TPST

Tempest Therapeutics Inc (NASDAQ:TPST) released new results from an ongoing Phase 1b/2 study of TPST-1120 in the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). The study shows TPST-1120's clinical superiority in multiple endpoints when combined with atezolizumab and bevacizumab. The confirmed objective response rate was 30% for the TPST-1120 arm versus 13.3% for the control arm. The progression-free survival was a median of 7 months for the TPST-1120 arm versus 4.27 months for the control arm. TPST shares are up 800.40% at $2.16 during the premarket session on the last check Wednesday.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 1:24 pm

VJET

Voxeljet (NASDAQ:VJET) has been selected by GE Research for a $14.9M contract funded by the U.S. Department of Energy (DoE) to develop advanced manufacturing technologies. The project aims to develop a voxeljet sand binder jet 3D printer for manufacturing large sand-casting molds, which will be used to produce metallic near net shape (NNS) components for the wind and hydro energy sectors. The goal is to reduce production time and costs, with the potential to reduce overall hydropower costs by 20% and lead times by four months.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:16 pm

ANAB

AnaptysBio is set to present Phase 1 data on ANB032, its BTLA agonist antibody, at the 32nd EADV Congress. This could potentially impact the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:16 pm

TPST

Tempest Therapeutics has released new data showing the superiority of TPST-1120 arm across multiple study endpoints in a first-line hepatocellular carcinoma study. This has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:13 pm

BCT

BCTX

BCTXW

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW) (TSX:BCT) will host a virtual Key Opinion Leader (KOL) event on October 26, 2023, to discuss the potential of Bria-IMT™ in advanced metastatic breast cancer. The event will feature Dr. Adam M. Brufsky from the University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic. BriaCell recently reported patient survival and clinical benefit with median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients. Bria-IMT™ has been awarded Fast Track status by the U.S Food and Drug Administration for the treatment of advanced metastatic breast cancer and initiated a phase 3 pivotal registration study.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:11 pm

AAPL

Apple Inc.'s 13-inch MacBook Air, powered by the M1 chipset, is now available at a $330 discount on Woot. The deal applies to the 16GB RAM and 256GB SSD configuration in the Space Gray color option.

Portfolio Pulse from Rounak Jain

October 11, 2023 | 1:10 pm

IOT

Samsara Inc. (NYSE:IOT) has announced its growth in the U.S. public sector, with the City of Houston being the latest to digitize its operations using Samsara's Connected Operations Cloud. The company's platform is being used to increase service transparency, sustainability, and safety, and to take data-informed actions. Other customers include the State of New Jersey, City of Fresno, and Hernando County. Samsara's recent fiscal quarter results showed that two of its top-five new customers and two of its top-five expansion deals were within the public sector.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:07 pm